Details

Autor(en) / Beteiligte

• Wartenberg, Martin
• Cibin, Silvia
• Zlobec, Inti
• Vassella, Erik
• Eppenberger-Castori, Serenella
• Terracciano, Luigi
• Eichmann, Micha David
• Worni, Mathias
• Gloor, Beat
• Perren, Aurel
• Karamitopoulou, Eva

Titel

Integrated Genomic and Immunophenotypic Classification of Pancreatic Cancer Reveals Three Distinct Subtypes with Prognostic/Predictive Significance

Ist Teil von

• Clinical cancer research, 2018-09, Vol.24 (18), p.4444-4454

Ort / Verlag

United States

Erscheinungsjahr

2018

Quelle

Electronic Journals Library

Beschreibungen/Notizen

• Current clinical classification of pancreatic ductal adenocarcinoma (PDAC) is unable to predict prognosis or response to chemo- or immunotherapy and does not take into account the host reaction to PDAC cells. Our aim is to classify PDAC according to host- and tumor-related factors into clinically/biologically relevant subtypes by integrating molecular and microenvironmental findings. A well-characterized PDAC cohort ( = 110) underwent next-generation sequencing with a hot spot cancer panel while next-generation tissue microarrays were immunostained for CD3, CD4, CD8, CD20, PD-L1, p63, hyaluronan-mediated motility receptor (RHAMM), and DNA mismatch repair proteins. Previous data on FOXP3 were integrated. Immune cell counts and protein expression were correlated with tumor-derived driver mutations, clinicopathologic features (TNM 8th edition, 2017), survival, and epithelial-mesenchymal transition (EMT)-like tumor budding. Three PDAC subtypes were identified: the "immune escape" (54%), poor in T and B cells and enriched in FOXP3 regulatory T cells (Treg), with high-grade budding, frequent , , and mutations, and poor outcome; the "immune rich" (35%), rich in T and B cells and poorer in FOXP3 Tregs, with infrequent budding, lower and mutation rate, and better outcome and a subpopulation with tertiary lymphoid tissue (TLT), mutations in DNA damage response genes ( and ), and the best outcome; and the "immune exhausted" (11%), with immunogenic microenvironment and two subpopulations-one with PD-L1 expression and a high mutation rate and a microsatellite-unstable subpopulation with a high prevalence of mutations. The combination of low budding, low stromal FOXP3 counts, presence of TLTs, and absence of mutations confers significant survival advantage in patients with PDAC. Immune host responses correlate with tumor characteristics, leading to morphologically recognizable PDAC subtypes with prognostic/predictive significance. .